"Many times they work well with mice and they don't work well with humans," Folkman said.
He said he believes his work will eventually have a tangible result on cancer treatment.
"We're optimistic because of the animal work," Folkman said. "We do think that angiogenesis inhibitors will be added to chemotherapy."
A Maryland company, EntreMed Inc., is funding the clinical trials of 2ME2.
Mary Sundeen, a spokesperson for Entremed, said clinical testing of 2ME2 has returned encouraging data, suggesting that the drug may be effective in fighting multiple myeloma, an aggressive type of cancer.
"The data-driven process has led us to believe the angiogenesis mechanism may make 2ME2 good for myeloma," Sundeen said. Sundeen said it showed promise in treating breast cancer.
2ME2 has received much less media attention than Endostatin, a similar drug that is injected instead of taken orally.
Read more in News
Wharton To Open San Francisco BranchRecommended Articles
-
Cancer Cure AnticipatedDue to the pioneering research of Dr. M. Judah Folkman, Dyckman Professor of Pediatric Surgery at Children's Hospital and Professor
-
Folkman Battles Cancer, SpotlightThe cure for cancer might be modern medicine's holy grail, the greatest medical discovery since the polio vaccine. Andrus Professor
-
Folkman Finds Anti-Cancer SubstanceResearchers at Boston Children's Hospital have discovered a naturally occurring protein fragment which has been shown to inhibit tumor growth
-
New Trials For Anti-Cancer Drug StartAfter decades of research, Andrus Professor of Pediatric Surgery M. Judah Folkman is one step closer to his research goal
-
HMS Researchers Use New Technique To Cure Cancer in MiceA group of Harvard researchers at Boston Children's Hospital say they have cured cancer in mice by applying new methodology
-
No Cure Yet, But Success at an Early StageUsing tools no more complicated than a microscope, a calculator and some common sense, cancer researchers at Harvard Medical School
